

[Lose 10 Lbs](#)
[- eDiets.com](#)
[Get a Free](#)
[Diet Profile](#)



U.S. ONLY
DEDICATED
 A non-profit organization

Yahoo! Health

[Home](#) > [Medication or Drug](#)

Search Again

 [Medication or Drug](#)

Search [alphabetically](#)

Yahoo! Categories

- [Drugs and Medications](#)
- [Pharmaceutical Companies](#)
- [Pharmacies](#)
- [Substance Abuse](#)

Yahoo! Community

- [Clubs: Drugs and Medications](#)
- [Events: Drugs and Medications](#)
- [Message Boards: Drugs and Medications](#)

Yahoo! Resources

- [Find a Doctor](#)
- [Health Assessment Test](#)
- [Yellow Pages: Pharmacies](#)

Paclitaxel (Injection)

[Print this article](#)

Overview | [Precautions](#)

DESCRIPTION

Treats cancer of the ovaries and the breast. Also used to treat some kinds of lung cancer, and an AIDS-related cancer called Kaposi's sarcoma.

Brand Name(s): Taxol®

WHEN YOU SHOULD NOT USE THIS MEDICINE

You should not be treated with this medicine if you have had an allergic reaction to paclitaxel.

HOW TO USE AND STORE THIS MEDICINE

This medicine, like all medicines used to treat cancer, is very strong. Make sure you understand why you are getting it and what the risks and benefits of treatment are. It is important for you to work closely with your doctor.

Intravenous (IV):

- Your doctor will prescribe your exact dose and tell you how often it will be given.
- Your medicine will be given through a tube put in one of your veins, usually in your arm, wrist, or hand and sometimes in your chest. This is called intravenous (in-tra-VEEN-us), or IV.
- A nurse or other caregiver trained to give cancer drugs will give your treatment.
- If you get your treatments at a clinic, the staff at the clinic will keep your medicine there.
- If you get your treatments at home, you may need to store your medicine. Keep the IV liquid at room temperature, away from heat and light. Do not use after the expiration date and time on the medicine label.
- Keep all medicine out of the reach of children.
- If you get your treatments at home, you should be given a special container for the used needles, medicine bag or bottles, and tubes. Put it where children or pets cannot reach it.

Put it where children or pets cannot reach it.

If you miss a dose:

- This medicine needs to be given on a regular schedule. If you miss a dose, call your doctor, home health caregiver, or clinic where you get your treatments for instructions.


Overview | Precautions

Copyright © 2001 Yahoo! Inc. All Rights Reserved.

Copyright © 2001 Medical Economics Company, Inc. All rights reserved.

Important Disclaimers - Privacy Practices for Yahoo! Health

The information contained above is intended for general reference purposes only. It is not a substitute for professional medical advice or a medical exam. Always seek the advice of your physician or other qualified health professional before starting any new treatment. Medical information changes rapidly and while Yahoo and its content providers make efforts to update the content on the site, some information may be out of date. No health information on Yahoo, including information about herbal therapies and other dietary supplements, is regulated or evaluated by the Food and Drug Administration and therefore the information should not be used to diagnose, treat, cure or prevent any disease without the supervision of a medical doctor.



[E-Mail Article](#)
[Print Article](#)
[Printing FAQ](#)



NCI Fact Sheet: Paclitaxel (Taxol) and Related Anticancer Drugs - Updated 02/2000

Affiliations: National Cancer Institute

Paclitaxel (Taxol) and Related Anticancer Drugs

Paclitaxel (Taxol-R) is a compound originally isolated from the bark of the Pacific yew tree (*Taxus brevifolia*). It has been approved by the U.S. Food and Drug Administration (FDA) to treat breast, ovarian, and lung cancers as well as AIDS-related Kaposi's sarcoma.

Paclitaxel has a unique way of preventing the growth of cancer cells: it affects cell structures called microtubules, which play an important role in cell functions. In normal cell growth, microtubules are formed when a cell starts dividing. Once the cell stops dividing, the microtubules are broken down or destroyed. Paclitaxel stops the microtubules from breaking down. With paclitaxel, cancer cells become so clogged with microtubules that they cannot grow and divide.

Early Research In 1984, NCI began clinical trials (research studies with people) that looked at paclitaxel's safety and how well it worked to treat certain cancers. In 1989, NCI-supported researchers at The Johns Hopkins Oncology Center reported that tumors shrank or disappeared in 30 percent of patients who were being given paclitaxel for the treatment of advanced ovarian cancer. Although the responses to paclitaxel were not permanent (they lasted an average of 5 months, some up to 9 months), it was clear that advanced ovarian cancer patients could benefit from the treatment. In December 1992, FDA approved the use of paclitaxel for ovarian cancer that was resistant to treatment (refractory).

Other clinical trials using paclitaxel have shown that the drug is effective

Main Menus:

[Types of Cancer](#)
[Cancer Treatments](#)
[Coping with Cancer](#)
[Screening/Prevention](#)
[Cancer News](#)
[Clinical Trials](#)
[Global Resources](#)
[Cancer FAQs](#)
[Symptom Management](#)
[Conferences and Meetings](#)
[Financial Issues](#)
[Book Reviews](#)

Featured Pages:

[About OncoLink](#)
[Editorial Board](#)
[Sponsors](#)
[Today's OncoTip](#)
[Usage Statistics](#)
[Virtual Classroom](#)

"Confronting Cancer Through Art" is an exhibition by people whose lives have been touched by cancer.



This week we are featuring artwork by: Kathleen Chapman Cheltenham, Pennsylvania



[Visit the Children's Art Gallery](#)

This week's artwork was donated by Allison

, a pediatric cancer patient who received treatment at [The Children's Hospital of Philadelphia](#).

in the treatment of advanced breast cancer. In April 1994, FDA approved paclitaxel for treating breast cancers that recur within 6 months after adjuvant chemotherapy (chemotherapy that is given after the primary treatment to enhance the effectiveness of the primary treatment). At that time, it was also approved for breast cancer that has spread (metastasized) and has not responded to combination chemotherapy.

In August 1997, paclitaxel was also approved by the FDA as a treatment for the AIDS-related cancer called Kaposi's sarcoma. In April 1998, it was approved for first-line therapy for the treatment of ovarian cancer in combination with cisplatin. Most recently, in June 1998, the FDA approved paclitaxel, in combination with other anticancer drugs, to treat common forms of advanced lung cancer.

Like most cancer drugs, paclitaxel has side effects that can be serious. It is important for patients to talk with their doctor about possible side effects from paclitaxel. For example, it can cause temporary damage to the bone marrow. The bone marrow is the soft, sponge-like tissue in the center of large bones that produces cells that fight infection, carry oxygen, and help prevent bleeding by causing blood clots to form. This damage can cause a person to bruise or bleed easily and be more susceptible to infection. However, the benefits for many patients with advanced cancer outweigh the risks associated with this drug.

Current Clinical Trials Researchers continue to look for new and better ways to use paclitaxel to treat cancer. For example, they are studying paclitaxel for treatment of early breast, ovarian, and lung cancer. Preliminary findings from ongoing clinical trials suggest that combining paclitaxel with other anticancer drugs may be an effective treatment for patients with lymph node-positive breast cancer. Other studies are looking at paclitaxel as a treatment for lymphomas, and stomach, head and neck, and bladder cancers. In addition, researchers are studying ways to overcome some cancers' resistance to paclitaxel.

Paclitaxel Supplies: Old Problems and New Approaches Early research using paclitaxel was limited due to difficulties in obtaining the drug. The amount of paclitaxel in yew bark is low, and extracting it is a complicated and expensive process. In addition, bark collection is restricted because the Pacific yew is a limited resource located in forests that are home to the endangered spotted owl.

As demand for paclitaxel grew, NCI, in collaboration with other Government agencies and Bristol-Myers Squibb, worked to increase the availability of paclitaxel. Bark collection and processing expanded to increase the short-term supply of the drug while NCI encouraged research to find other sources of paclitaxel and related compounds.

One option is to synthesize paclitaxel. Currently, a semi-synthetic form of the drug is being studied. To produce the semi-synthetic drug, a substance from the needles of yew trees grown for this purpose is

chemically changed to produce paclitaxel.

Another alternative is docetaxel (Taxotere-R), a substance that is similar to paclitaxel. Docetaxel, like the semi-synthetic paclitaxel, comes from the needles of the yew tree. Docetaxel has been approved by the FDA to treat advanced breast and nonsmall cell lung cancers that have not responded to other anticancer drugs. The side effects of docetaxel are similar to those related to paclitaxel. The NCI is sponsoring clinical trials to test the effectiveness of docetaxel alone or in combination with other anticancer drugs for several types of cancer, including cancers of the head and neck, prostate, breast, lung, and uterus.

This fact sheet was reviewed on 2/10/00

National Cancer Institute Information Resources

You may want more information for yourself, your family, and your doctor. The following National Cancer Institute (NCI) services are available to help you.

Telephone...

Cancer Information Service (CIS) Provides accurate, up-to-date information on cancer to patients and their families, health professionals, and the general public. Information specialists translate the latest scientific information into understandable language and respond in English, Spanish, or on TTY equipment. Toll-free: **1-800-4-CANCER** (1-800-422-6237) TTY: 1-800-332-8615

Internet...

These web sites may be useful: <http://www.nci.nih.gov> - NCI's primary web site; contains information about the Institute and its programs.

<http://cancernet.nci.nih.gov> - CancerNet; contains material for health professionals, patients, and the public, including information from PDQ about cancer treatment, screening, prevention, supportive care, and clinical trials, and **CANCERLIT**, a bibliographic database.

<http://cancertrials.nci.nih.gov> - cancerTrials; NCI's comprehensive clinical trials information center for patients, health professionals, and the public. Includes information on understanding trials, deciding whether to participate in trials, finding specific trials, plus research news and other resources.

E-mail...

CancerMail Includes NCI information about cancer treatment, screening, prevention, and supportive care. To obtain a contents list, send e-mail to

cancermail@icicc.nci.nih.gov with the word "help" in the body of the message.

Fax...

CancerFax Includes NCI information about cancer treatment, screening, prevention, and supportive care. To obtain a contents list, dial 301-402-5874 from a fax machine hand set and follow the recorded instructions.

PDQ statements exist for a number of topics. Please consult the PDQ Index.

This document is also available in a text-only format.



GENERAL DISCLAIMER

OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

ONCOLINK PRIVACY STATEMENT

*For further information, consult the Editors at:
editors@oncolink.upenn.edu*